CDC reports  heart inflammation was higher than expected in 16- to 24-year-olds after receiving the second Covid-19 vaccine shot

 

 

Young adults that received the Pfizer’s or Moderna’s second shot of the COVID vaccine were reported to have more heart inflammation than expected.

Cases of myocarditis or pericarditis were reported in the young adults.

U.S. health officials are investigating a higher-than-expected reporting’s of heart inflammation in male teens and young adults after their second dose of the Pfizer and Moderna vaccines.

As of May 31, the CDC agency had 275 preliminary reports of inflammation in 16- to 24-year-olds, CDC’s Dr. Tom Shimabukuro said in  a government vaccine meeting on Thursday. “That’s out of more than 12 million second-dose injections of the vaccines.”

However, it is still unclear if the heart inflammation is caused by the shots. The reports are currently rare according to the Centers for Disease Control and Prevention. It recommends everyone 12 and older to get vaccinated.

The CDC’s vaccine advisory committee meets on June 18 to further evaluate the possible risk.


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer


>